40 completed, 5 unknown, 4 withdrawn, 3 recruiting. 56 Phase 2, 7 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 56 | Completed 40, Unknown 5, Withdrawn 4, Recruiting 3, Terminated 3, Enrolling by invitation 1 |
| Phase 1 | 7 | Completed 5, Withdrawn 2 |
| Phase 3 | 2 | Completed 2 |
Follow Rosacea: new trials by email Literature Review of Rosacea trials Research Report on Rosacea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR) LOU064, Placebo - Papulopustular Rosacea | Phase 2 | Recruiting | Novartis Pharmaceuticals | 100 | 2026-07-30 | 2026-11-10 |
| Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE) lotilaner, Vehicle - Ocular Rosacea | Phase 2 | Enrolling by invitation | Tarsus Pharmaceuticals, Inc. | 155 | 2025-12-05 | 2026-03-02 |
| Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea Clascoterone Cream 1% - Papular-pustular Rosacea, Papulopustular Rosacea (PPR) | Phase 2 | Recruiting | Narrows Institute for Biomedical Research | 20 | 2025-03-14 | 2025-05-06 |
| Deucravacitinib Rosacea Deucravacitinib, Placebo - Papulopustular Rosacea | Phase 2 | Withdrawn | Icahn School of Medicine at Mount Sinai | 2024-11-01 | 2025-01-24 | |
| Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea Imipramine, Amitriptyline, Vehicle - Rosacea | Phase 2 | Recruiting | Wright State University | 48 | 2024-02-27 | 2026-02-18 |
| Study to Evaluate the Safety of ATR-04 ATR-04, Placebo - Epidermal Growth Factor, Papulopustular Rosacea | Phase 1 / Phase 2 | Withdrawn | Azitra Inc. | 2024-01-01 | 2025-10-03 | |
| Potassium-titanyl Phosphate (KTP) Laser vs KTP Laser and Ivermectin Cream for Facial Rosacea KTP laser, Ivermectin 1% cream - Rosacea | Phase 2 | Completed | Insel Gruppe AG, University Hospital Bern | 22 | 2023-09-12 | 2024-12-06 |
| PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea PF-07038124, Placebo Ointment - Seborrheic Dermatitis, Papulopustular Rosacea | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 32 | 2023-07-19 | 2026-08-14 |
| Study of TP-04 in Participants With Papulopustular Rosacea Lotilaner Gel, 2.0%, Vehicle control gel - Papulopustular Rosacea | Phase 2 | Completed | Tarsus Pharmaceuticals, Inc. | 37 | 2023-03-01 | 2023-11-24 |
| Evaluation of the Safety and Efficacy of Topical Roflumilast Cream in the Treatment of Facial Papulopustular Rosacea Roflumilast Cream - Rosacea | Phase 2 | Completed | Dermatology Consulting Services, PLLC | 40 | 2022-04-15 | 2023-05-31 |
| DMT310-005 Topical in the Treatment of Acne Rosacea Topical Powder, Placebo Topical Powder - Acne Rosacea | Phase 2 | Unknown | Dermata Therapeutics | 180 | 2021-11-15 | 2022-12-08 |
| Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea Rifaximin, Placebo - Papulopustular Rosacea | Phase 2 | Completed | Alfasigma S.p.A. | 216 | 2021-10-05 | 2024-04-24 |
| Therapeutic Effects of Topical Herbal Medicine -Rhubarb Ointment on Rosacea dian dao san - Rosacea, Chinese Herbal Medicine | Phase 2 | Completed | Chang Gung Memorial Hospital | 24 | 2021-08-04 | 2025-04-01 |
| A Safety and Efficacy Study to Evaluate Rosacea AIV001, Vehicle - Papulopustular Rosacea | Phase 1 / Phase 2 | Withdrawn | AiViva BioPharma, Inc. | 2021-07-01 | 2024-12-17 | |
| CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea CGB-400, Vehicle Gel - Rosacea | Phase 2 | Completed | CAGE Bio Inc. | 78 | 2021-05-07 | 2026-04-01 |
| Rosacea and Ivermectin ivermectin, digital interaction, GPSkin - Rosacea | Phase 2 | Completed | Wake Forest University Health Sciences | 30 | 2021-04-16 | 2026-03-27 |
| Efficacy and Tolerability of Erenumab in the Management of Persistent Redness and Flushing in Rosacea AMG 334 - Rosacea | Phase 2 | Unknown | Messoud Ashina | 30 | 2020-06-09 | 2020-06-11 |
| Evaluation of Topical Application of BMX-010 in Subjects With Rosacea BMX-010 - Rosacea | Phase 2 | Terminated | BioMimetix JV, LLC | 6 | 2019-02-20 | 2026-11-05 |
| Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea minocycline topical gel, topical gel vehicle - Papulopustular Rosacea | Phase 2 | Unknown | BioPharmX, Inc. | 207 | 2018-09-18 | 2019-07-10 |
| A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea B244, Vehicle - Rosacea | Phase 2 | Completed | AOBiome LLC | 140 | 2018-07-02 | 2022-09-16 |
Showing 20 of 56. Sign in to see all of them.
Erythema (4) · Acne Vulgaris (2) · Dermatitis, Seborrheic (2) · Skin Diseases (2) · Telangiectasis (2) · cyclopia sequence (2) · Corneal Neovascularization (1) · Dermatitis, Atopic (1) · Flushing (1) · Primary hyperoxaluria type 2 (1)
Skin and Connective Tissue Diseases (56) · Skin Diseases (54) · Pathological Conditions, Signs and Symptoms (5) · Signs and Symptoms (4) · Skin Manifestations (4) · Sebaceous Gland Diseases (3) · Acneiform Eruptions (2) · Cardiovascular Diseases (2) · Dermatitis (2) · Skin Diseases, Eczematous (2) · Skin Diseases, Papulosquamous (2) · Vascular Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Corneal Diseases (1) · Eye Diseases (1)
Gels (3) · Ivermectin (3) · Rifaximin (2) · azelaic acid (2) · Amitriptyline (1) · Benchmarking (1) · Capsules (1) · Clascoterone (1) · Cromolyn Sodium (1) · Dapsone (1) · Doxycycline (1) · Imipramine (1) · Lasers, Solid-State (1) · Metronidazole (1) · N-(1-(3,5-difluoro-4-methanesulfonylaminophenyl)ethyl)-3-(2-propyl-6-trifluoromethylpyridine-3-yl)acrylamide (1)
Galderma R&D (3) · Alfasigma S.p.A. (2) · Allergan (2) · Amorepacific Corporation (2) · Dermata Therapeutics (2) · Dr. Reddy's Laboratories Limited (2) · Icahn School of Medicine at Mount Sinai (2) · LEO Pharma (2) · Novartis Pharmaceuticals (2) · Tarsus Pharmaceuticals, Inc. (2) · University of California, San Diego (2) · Vyne Therapeutics Inc. (2) · AOBiome LLC (1) · Accuitis, Inc. (1) · AiViva BioPharma, Inc. (1)
United States (42) · Germany (5) · Canada (3) · South Korea (3) · Italy (2) · Bulgaria (1) · China (1) · Denmark (1) · Israel (1) · Singapore (1) · Spain (1) · Switzerland (1) · Taiwan (1)
Michael Graeber, MD (2) · Alan Fleischer, MD (1) · Alexa Kimball, MD, MPH (1) · Andrew Pollack, MD (1) · Angela Moore, MD (1) · AnnaMarie Daniels (1) · Anne Chang, MD (1) · Benjamin Ungar (1) · Benjamin Ungar, MD (1) · BeomJoon Kim, Professor (1) · Beth Zib (1) · Daniel M Stewart, DO (1) · Dow Stough, MD (1) · Eduardo Tschen, MD (1)
PMID 22395584, PMID 23233252, PMID 29396702, PMID 34076401, PMID 35096250, PMID 38630457, PMID 41778357
2017 (1), 2025 (1)